Skip to main content

Table 1 Baseline characteristics of the PROSPER/PHASE study

From: Replication of LDL GWAs hits in PROSPER/PHASE as validation for future (pharmaco)genetic analyses

  PROSPER study (n = 5804) PROSPER/PHASE study (n = 5244)
Continuous variables (mean, SD)   
   Age (years) 75.3 (3.3) 75.3 (3.4)
   Education (years) 15.1 (2.0) 15.1 (2.0)
   Systolic blood pressure (mmHg) 154.7 (21.8) 154.6 (21.9)
   Diastolic blood pressure (mmHg) 83.8 (11.5) 83.7 (11.4)
   Height (cm) 165.2 (9.4) 165.2 (9.4)
   Weight (kg) 73.4 (13.4) 73.3 (13.4)
   Body mass index (kg/m2) 26.8 (4.2) 26.8 (4.2)
   Total cholesterol (mmol/L) 5.7 (0.9) 5.7 (0.9)
   LDL cholesterol (mmol/L) 3.8 (0.8) 3.8 (0.8)
   HDL cholesterol (mmol/L) 1.3 (0.3) 1.3 (0.4)
   Triglycerides (mmol/L) 1.5 (0.7) 1.5 (0.7)
Categorical variables (n, %)   
   Males 2804 (48.3) 2524 (48.1)
   Current smoker 1558 (26.8) 1392 (26.5)
   History of diabetes 623 (10.7) 544 (10.4)
   History of hypertension 3592 (61.9) 3257 (62.1)
   History of angina 1559 (26.9) 1424 (27.2)
   History of claudication 390 (6.7) 354 (6.8)
   History of myocardial infarction 776 (13.4) 708 (13.5)
   History of stroke or TIA 649 (11.2) 586 (11.2)
   History of vascular disease* 2565 (44.2) 2336 (44.5)
  1. *Any of stable angina, intermittent claudication, stroke, transient ischemic attack, myocardial infarction, peripheral artery disease surgery, or amputation for vascular disease more than 6 months before study entry.